ARA-290 (Cibinetide) Peptide

ARA-290 (Cibinetide) is a non-erythropoietic EPO-derived peptide that activates the Innate Repair Receptor. It provides tissue protection and anti-inflammatory effects without stimulating red blood cell production.

ARA-290 (cibinetide) is an 11-amino acid linear peptide whose sequence corresponds to the aqueous-exposed face of helix B of erythropoietin (EPO). It was rationally designed to dissociate the cytoprotective and tissue-repair activities of EPO from its hematopoietic effects, exploiting the fact that these two activity profiles are mediated by structurally distinct receptor complexes.

Selective Activation of the Innate Repair Receptor (IRR)

Classical EPO signaling in erythroid progenitors occurs through a homodimer of the erythropoietin receptor (EPOR₂). In contrast, tissue-protective signaling occurs through a heteromeric complex composed of EPOR and the common β-chain (CD131, βcR) shared with GM-CSF, IL-3 and IL-5 receptors. This EPOR/βcR heterocomplex is termed the innate repair receptor (IRR). ARA-290 binds the IRR with nanomolar affinity but does not engage EPOR₂ homodimers, producing tissue-protective effects without stimulating erythropoiesis, platelet activation, or elevations in hematocrit.[1]

Downstream Signaling Cascades

Engagement of the IRR activates several intracellular pathways implicated in cell survival and resolution of inflammation:

• JAK2/STAT3 and STAT5 — antiapoptotic gene expression (Bcl-xL, Mcl-1).
• PI3K/AKT — inhibition of GSK-3β and pro-apoptotic BAD phosphorylation.
• MAPK (ERK1/2) — cytoprotection and modulation of proliferation in repair-competent cells.
• NF-κB modulation — reduced transcription of TNF-α, IL-6, and IL-1β in activated macrophages.

Anti-inflammatory and Neurotrophic Effects

In preclinical models, ARA-290 reduces pro-inflammatory cytokine release from activated immune cells, attenuates neutrophil infiltration, and decreases oxidative stress in injured tissue. In sensory neurons, IRR activation has been associated with restoration of small nerve fiber density and improvement of corneal nerve fiber metrics, suggesting a neurotrophic component relevant to small fiber neuropathy research.[2]

Differentiation from Erythropoietin

Unlike EPO, ARA-290 has a plasma half-life of only ~2 minutes, yet produces biological effects lasting hours to days, consistent with receptor-mediated hit-and-run signaling. Because it does not bind EPOR₂, ARA-290 lacks the thrombotic and hypertensive liabilities that limit chronic EPO administration, making it a useful tool compound for dissecting the cytoprotective arm of EPO biology in research models.

ARA-290 (cibinetide) is a short linear peptide derived from the helix B surface of human erythropoietin. The N-terminal glutamine is typically cyclized to pyroglutamate (pyr-Glu), which confers resistance to aminopeptidase degradation. The compound contains no disulfide bridges and no non-natural amino acids, making it relatively straightforward to handle compared with cysteine-rich peptides.

The peptide is supplied as a lyophilized powder under inert gas to minimize oxidation. Because the sequence lacks methionine, tryptophan, and cysteine, ARA-290 is comparatively stable against oxidative degradation, though general best practices for peptide handling still apply.

ARA-290 (cibinetide) is supplied as a sterile, lyophilized white powder intended for laboratory research use only. Proper reconstitution preserves the structural integrity of the 11-residue helix B surface peptide and ensures reproducible activity in cell-based and in vivo research models. Because ARA-290 is highly water-soluble and does not contain disulfide bridges, reconstitution is straightforward, but standard aseptic technique should be observed.

Recommended Reconstitution Protocol

1. Equilibrate the vial to room temperature (15-25°C) for 20-30 minutes before opening. This prevents condensation from forming on the cold lyophilizate when the stopper is pierced.
2. Briefly centrifuge the vial (if a benchtop microcentrifuge is available) to ensure all powder is at the base before introducing diluent.
3. Select diluent: Bacteriostatic water for injection (0.9% benzyl alcohol) is preferred for multi-day studies; sterile water for injection or 0.9% sodium chloride is acceptable for single-use preparations.
4. Add diluent slowly down the inner wall of the vial — do not inject directly onto the powder cake. A typical preparation is 5 mg + 2 mL = 2.5 mg/mL, or 10 mg + 2 mL = 5 mg/mL.
5. Dissolve gently by swirling the vial in a slow circular motion or inverting 5-10 times. Do not shake or vortex — agitation can introduce shear stress, denature the peptide, and create foaming that reduces effective concentration.
6. Inspect the resulting solution. It should be clear and colorless with no visible particulates. If turbidity or particulates are present, discard and prepare a fresh vial.
7. Aliquot the reconstituted solution into low-binding sterile tubes if extended use is planned, to minimize freeze-thaw cycles.

Compound-Specific Handling Notes

• ARA-290 contains no methionine or cysteine residues, so methionine oxidation and disulfide scrambling are not concerns — a stability advantage over many EPO-derived constructs.
• The peptide is sensitive to repeated freeze-thaw cycles; limit to 3 or fewer.
• Protect from prolonged ambient light exposure during weighing and reconstitution.
• Use low-protein-binding pipette tips and storage vials to minimize adsorptive losses at low working concentrations (<100 µg/mL).

All handling should be conducted in accordance with the user's institutional biosafety guidelines. ARA-290 is not for human or veterinary use; it is intended exclusively for in vitro and in vivo laboratory research conducted by qualified investigators.

Proper storage of ARA-290 (cibinetide) is essential to maintain peptide integrity, IRR binding affinity, and reproducibility across long-term research programs. The compound's compact 11-residue structure and absence of disulfide bonds confer relatively favorable stability compared with larger erythropoiesis-stimulating proteins, but standard cold-chain practices remain critical.

Lyophilized Powder Storage

• Long-term (≥1 month): Store sealed lyophilized vials at -20°C in a manual-defrost freezer. Under these conditions, ARA-290 is typically stable for 24 months or longer from the date of manufacture, provided the desiccated environment is maintained.
• Short-term (≤30 days): Storage at 2-8°C in a refrigerator is acceptable for ongoing experimental campaigns where frequent access is required.
• Transit: Brief exposure to ambient temperature (up to 7 days) during shipping does not measurably degrade the lyophilized peptide, due to the absence of oxidation-prone residues.

Reconstituted Solution Storage

• After reconstitution in bacteriostatic water, store at 2-8°C and use within 28 days for highest reproducibility.
• For longer retention, aliquot into single-use volumes and store at -20°C or -80°C for up to 3 months. Avoid more than 2-3 freeze-thaw cycles.
• Allow frozen aliquots to thaw at 2-8°C rather than at room temperature to minimize local concentration gradients.

Compound-Specific Stability Notes

• ARA-290 contains no methionine, cysteine, or tryptophan residues, eliminating the most common oxidative degradation pathways seen in EPO and related peptides.
• The peptide is stable across a pH range of approximately 5-8; extremes of pH should be avoided in buffer selection.
• Adsorption to glass and polypropylene surfaces is minimal at concentrations above 0.5 mg/mL but can become significant at sub-microgram/mL working dilutions — carrier protein (e.g., 0.1% BSA) may be added for dilute working solutions.

Always document reconstitution date, diluent, and storage temperature on each vial to support data traceability and quality assurance.